A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
To the editor, Primary immunodeficiencies (PIDs) are a heterogeneous group of rare diseases that clinically manifest with infections, autoimmunity, inflammation, and malignancy as a result of impairment of one or more effector mechanisms of the immune system. Identification of the molecular cause underlying PID informs clinicians on management and best practise in these complex cases [1] .
Without a molecular diagnosis clinicians are often required to be reactive rather than proactive in treatment decisions, which can lead to an increased morbidity in PID patients. Knowledge of the aberrant molecular pathways in cases of PID is even more apparent now as the field of precision medicine expands within the discipline [2] . We highlight the utility of a non-bias investigational approach using whole exome sequencing to reach a genetic diagnosis in a case activated phosphoinositide 3-kinase δ syndrome (APDS) (OMIM 615513) that led to long-term clinical stability with a precision medicine approach.
A 4-year-old boy presented to a secondary care pediatric service with a three-day history of fever, abdominal pain, grunting and breathlessness. He had an unremarkable past medical history apart from three brief hospital admissions for rash and fever which were attributed to viral infections, and was Figure 3 ). This variant in PIK3CD has previously been reported to be pathogenic resulting in APDS [3, 4] . Patients with APDS suffer frequent sinopulmonary infections as a result of impaired humoral immunity as well as autoimmune phenomena and lymphoid hyperplasia due to immune dysregulation [3] .
Due to refractory AIHA, and the genetic results supporting over activity of the PI3K-AKT-mTOR pathway within the patient's lymphocytes, the mTOR inhibitor sirolimus was commenced as a precision medicine with the aim of controlling the hemolysis and reducing the lymphoid bulk [4] .
Previously sirolimus has also been reported to be successful in treating refractory autoimmune
cytopenias in PID conditions including common variable immunodeficiency and autoimmune lymphoproliferative syndrome [5, 6] .
After the initiation of sirolimus, in contrast to previous immunosuppressive regimes, there has been no relapse of hemolysis, infectious complications, and prednisolone has been withdrawn. His DAT has remained negative since commencing sirolimus. We have observed a reduction in lymphadenopathy volume, resolution in splenomegaly, and an improvement in the T cell senescence pattern with an increase in naive T cell percentages (Supplementary data Table 1 ). Sirolimus trough levels have fluctuated from 4.3 -11.8ng/ml (Supplementary data Table 5 ) with no clinical impact, suggesting the target dose range for sirolimus in APDS may be lower than in solid organ transplant recipients (10-15ng/ml). He has now remained well for over 18 months with no relapse of hemolysis and continues with sirolimus 2mg daily and immunoglobulin replacement treatment.
New genomic technologies, such as whole exome sequencing by next generation sequencing, are now available and affordable [7] . In primary immunodeficiency cases, knowledge of the molecular diagnosis and subsequent impacts on cellular pathway allow the identification of precision medicines targets that can significantly improve a patient's quality of life [8] . As with all medical investigations, genomic tests require careful selection of the test methodology and assessment of pre-test probability.
When undertaking whole exome sequencing in a patient specific consideration of informed consent, data analysis complexities, the reporting of incidental findings and impacts on the wider family is needed. The integration of genomic tests into routine clinical work has many challenges ahead, but
cases such as this demonstrate the powerful impact that the integration of genomic medicine can have on the diagnosis and treatment for patients across medical specialities [9] .

